... events resulted in treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of ... No single drug regimen can be considered standard. Some patients with distant ...

... to manage MTC. The use of vandetanib and cabozantinib is approved by the U.S. Food and ... A double-blind phase III trial that compared cabozantinib with placebo in 330 patients with progressive MTC ...

... NCI website and ClinicalTrials.gov website . ADVL1622 (NCT02867592) (Cabozantinib-S-Malate in Treating Younger Patients with Recurrent, ... open-label, two-stage, phase II trial of cabozantinib in selective solid tumors, including Ewing sarcoma. Cabozantinib ...

... symptoms have been reported with the use of cabozantinib in pediatric patients with translocation-positive RCC expressing ... MF, Ranalli M, Shah N: Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell ...

... occur in 30% to 90% of patients: - Bosutinib. - Cabozantinib. - Ceritinib. - Crizotinib. - Cyclophosphamide. - Imatinib. - Lenvatinib. - Temozolomide. - Trifluridine-tipiracil. - ...

... from the foretinib study,[ 25 ] agents such as cabozantinib (a multitargeted tyrosine kinase inhibitor with activity against ...